Applied StemCell

Biotechnology ResearchCalifornia, United States51-200 Employees

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies
Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases.

ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services.
Current Offerings:
• iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation
• Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation
• Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening
• Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models

For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Sign up for free to view info

Email Format Employee directory